Gregory M Chen
Overview
Explore the profile of Gregory M Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1172
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xu J, Chen C, Sussman J, Yoshimura S, Vincent T, Polonen P, et al.
Nat Cancer
. 2024 Nov;
6(1):102-122.
PMID: 39587259
Refractoriness to initial chemotherapy and relapse after remission are the main obstacles to curing T cell acute lymphoblastic leukemia (T-ALL). While tumor heterogeneity has been implicated in treatment failure, the...
2.
Dimitri A, Baxter A, Chen G, Hopkins C, Rouin G, Huang H, et al.
Sci Adv
. 2024 Nov;
10(46):eadp9371.
PMID: 39536093
CD8 T cell exhaustion hampers control of cancer and chronic infections and limits chimeric antigen receptor (CAR) T cell efficacy. Targeting in CAR T cells provides therapeutic benefit; however, TET2's...
3.
Doan A, Mueller K, Chen A, Rouin G, Chen Y, Daniel B, et al.
Nature
. 2024 Apr;
629(8011):E11.
PMID: 38654101
No abstract available.
4.
Doan A, Mueller K, Chen A, Rouin G, Chen Y, Daniel B, et al.
Nature
. 2024 Apr;
629(8010):211-218.
PMID: 38600391
A major limitation of chimeric antigen receptor (CAR) T cell therapies is the poor persistence of these cells in vivo. The expression of memory-associated genes in CAR T cells is...
5.
Melenhorst J, Chen G, Wang M, Porter D, Chen C, Collins M, et al.
Nature
. 2022 Dec;
612(7941):E22.
PMID: 36477542
No abstract available.
6.
Chen G, Chen C, Perazzelli J, Grupp S, Barrett D, Tan K
Cancer Immunol Res
. 2022 Oct;
11(1):13-19.
PMID: 36255409
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has been a clinical breakthrough for pediatric B-cell acute lymphoblastic leukemia (B-ALL), and loss of the CD19 target antigen on leukemic cells...
7.
Chen G, Melenhorst J, Tan K
Sci Transl Med
. 2022 Jun;
14(650):eabn3353.
PMID: 35731887
Chimeric antigen receptor (CAR) T cell therapies targeting CD19 and CD22 have been successful for treating B cell cancers, but CAR T cells targeting non-B cell cancers remain unsuccessful. We...
8.
Melenhorst J, Chen G, Wang M, Porter D, Chen C, Collins M, et al.
Nature
. 2022 Feb;
602(7897):503-509.
PMID: 35110735
The adoptive transfer of T lymphocytes reprogrammed to target tumour cells has demonstrated potential for treatment of various cancers. However, little is known about the long-term potential and clonal stability...
9.
Ding Y, Kim H, Madden K, Loftus J, Chen G, Allen D, et al.
Clin Cancer Res
. 2021 Jul;
27(18):5109-5122.
PMID: 34210682
Purpose: Systems biology approaches can identify critical targets in complex cancer signaling networks to inform new therapy combinations that may overcome conventional treatment resistance. Experimental Design: We performed integrated analysis...
10.
Chen G, Chen C, Das R, Gao P, Chen C, Bandyopadhyay S, et al.
Cancer Discov
. 2021 Apr;
11(9):2186-2199.
PMID: 33820778
The adoptive transfer of chimeric antigen receptor (CAR) T cells represents a breakthrough in clinical oncology, yet both between- and within-patient differences in autologously derived T cells are a major...